PL3721868T3 - Oftalmiczna kompozycja zawiesinowa - Google Patents

Oftalmiczna kompozycja zawiesinowa

Info

Publication number
PL3721868T3
PL3721868T3 PL20166312.7T PL20166312T PL3721868T3 PL 3721868 T3 PL3721868 T3 PL 3721868T3 PL 20166312 T PL20166312 T PL 20166312T PL 3721868 T3 PL3721868 T3 PL 3721868T3
Authority
PL
Poland
Prior art keywords
suspension composition
ophthalmic suspension
ophthalmic
composition
suspension
Prior art date
Application number
PL20166312.7T
Other languages
English (en)
Other versions
PL3721868T5 (pl
Inventor
Mohannad Shawer
Eric Phillips
Martin J. Coffey
Original Assignee
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55359733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3721868(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch & Lomb Incorporated filed Critical Bausch & Lomb Incorporated
Publication of PL3721868T3 publication Critical patent/PL3721868T3/pl
Publication of PL3721868T5 publication Critical patent/PL3721868T5/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20166312.7T 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa PL3721868T5 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562107696P 2015-01-26 2015-01-26

Publications (2)

Publication Number Publication Date
PL3721868T3 true PL3721868T3 (pl) 2022-11-07
PL3721868T5 PL3721868T5 (pl) 2025-12-22

Family

ID=55359733

Family Applications (5)

Application Number Title Priority Date Filing Date
PL18209003T PL3470059T3 (pl) 2015-01-26 2016-01-26 Kompozycja zawiesiny okulistycznej
PL20166312.7T PL3721868T5 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL23196938.7T PL4268850T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL22175139.9T PL4082531T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL16704744T PL3250185T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL18209003T PL3470059T3 (pl) 2015-01-26 2016-01-26 Kompozycja zawiesiny okulistycznej

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL23196938.7T PL4268850T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL22175139.9T PL4082531T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa
PL16704744T PL3250185T3 (pl) 2015-01-26 2016-01-26 Oftalmiczna kompozycja zawiesinowa

Country Status (15)

Country Link
US (3) US10596107B2 (pl)
EP (5) EP3250185B1 (pl)
JP (1) JP2018507252A (pl)
KR (1) KR102538370B1 (pl)
CN (1) CN107427464B (pl)
AU (4) AU2016211745A1 (pl)
BR (1) BR112017016016B1 (pl)
CA (1) CA2975106A1 (pl)
ES (5) ES2704125T3 (pl)
HU (5) HUE071679T2 (pl)
MX (1) MX390671B (pl)
PL (5) PL3470059T3 (pl)
PT (3) PT3721868T (pl)
SI (1) SI4268850T1 (pl)
WO (1) WO2016123079A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3470059T3 (pl) * 2015-01-26 2020-11-30 Bausch & Lomb Incorporated Kompozycja zawiesiny okulistycznej
CA3001955C (en) 2015-10-16 2023-11-28 Sun Pharma Advanced Research Company Limited Ophthalmic solution of difluprednate
EP3245988B1 (en) 2016-05-18 2023-12-27 Sonikure Holdings Limited System for ultrasound-enhanced transscleral delivery of drugs
WO2019036483A1 (en) 2017-08-15 2019-02-21 Nephron Pharmaceuticals Corporation AQUEOUS NEBULIZATION COMPOSITION
CN113227304A (zh) * 2018-09-21 2021-08-06 Ps治疗有限公司 人工泪液、隐形眼镜和药物载体组合物及其使用方法
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー 4-(7-ヒドロキシ-2-イソプロピル-4-オキソ-4h-キナゾリン-3-イル)-ベンゾニトリルの製剤
EP3924345A1 (en) * 2019-02-15 2021-12-22 Novartis AG Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof
EP4013443A4 (en) * 2019-08-18 2023-10-04 IVIEW Therapeutics (Zhuhai) Co., Ltd. IN-SITU GEL-CONTAINING CYCLOSPORINE MICELLARS AS A SYSTEM FOR THE DELAYED RELEASE OF OPHTHALMIC ACTIVE INGREDIENTS
KR102271247B1 (ko) * 2020-11-04 2021-06-30 삼천당제약주식회사 안과용 현탁액 조성물의 제조방법
CN115554238A (zh) * 2022-10-25 2023-01-03 苏州欧康维视生物科技有限公司 眼用混悬液及其制备方法
CN115887372A (zh) * 2022-10-25 2023-04-04 苏州欧康维视生物科技有限公司 丙酸氟替卡松混悬液及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
DE3486448T2 (de) 1983-11-14 1997-10-09 Columbia Lab Inc Bioadhäsive Mittel
NZ226171A (en) 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
IE63392B1 (en) 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2134376C (en) 1993-12-20 2001-10-23 Haresh G. Bhagat Combinations of polymers for use in physiological tear compositions
US5556848A (en) * 1993-12-27 1996-09-17 Senju Pharmaceutical Co., Ltd. Ophthalmic suspension containing diflupredonate
GB9718568D0 (en) * 1997-09-03 1997-11-05 Chauvin Pharmaceuticals Limite Compositions
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
AR033151A1 (es) * 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc Agente para el tratamiento oftalmico topico de las enfermedades inflamatorias oculares
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
CA2839847C (en) 2003-06-13 2016-03-15 Masood A. Chowhan Ophthalmic compositions containing a synergistic combination of two polymers
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050182039A1 (en) * 2004-02-13 2005-08-18 Bausch & Lomb Incorporated Use of Loteprednol etabonate for the treatment of dry eye
TWI358290B (en) 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20120028947A1 (en) 2005-11-14 2012-02-02 Erning Xia Ophthalmic Compositions
WO2007058935A2 (en) 2005-11-14 2007-05-24 Bausch & Lomb Incorporated Ophthalmic composition for dry eye therapy
US20100234336A1 (en) 2005-11-14 2010-09-16 Erning Xia Ophthalmic Compositions
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
CN101966143A (zh) 2009-07-28 2011-02-09 胡容峰 加替沙星温度及pH敏感眼用凝胶的制备与应用
PL2506831T3 (pl) 2009-12-03 2014-05-30 Alcon Res Ltd Zawiesiny zawierające nanocząsteczkowe polimery karbowinylowe
WO2013043387A1 (en) * 2011-09-22 2013-03-28 Bausch & Lomb Incorporated Ophthalmic gel compositions
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
PT3517541T (pt) 2012-05-08 2020-08-28 Nicox Ophthalmics Inc Forma polimórfica de propionato de fluticasona
WO2013168437A1 (ja) * 2012-05-11 2013-11-14 株式会社アクティバスファーマ 有機化合物ナノ粉体、その製造方法ならびに懸濁液
EP2890363A1 (en) 2012-08-31 2015-07-08 Bausch & Lomb Incorporated Ophthalmic compositions with omega-3 fatty acids
US20150190407A1 (en) 2014-01-07 2015-07-09 Insite Vision Incorporated Methods for treatment of postoperative inflammation with reduced intraocular pressure
CN106572971B (zh) 2014-07-11 2020-09-15 富士胶片株式会社 眼科用水性组合物的制造方法及眼科用水性组合物
AU2015288644B2 (en) 2014-07-11 2017-12-14 Fujifilm Corporation Aqueous ophthalmic composition
ES2951202T3 (es) 2014-07-28 2023-10-19 Sun Pharma Advanced Res Co Ltd Método para aumentar la biodisponibilidad y/o prolongar la acción oftálmica de un fármaco
PL3470059T3 (pl) * 2015-01-26 2020-11-30 Bausch & Lomb Incorporated Kompozycja zawiesiny okulistycznej

Also Published As

Publication number Publication date
EP3470059A1 (en) 2019-04-17
ES2966595T3 (es) 2024-04-23
EP4082531A1 (en) 2022-11-02
HUE059639T2 (hu) 2022-12-28
HUE041945T2 (hu) 2019-06-28
EP4268850A1 (en) 2023-11-01
EP3470059B1 (en) 2020-04-01
ES2787039T3 (es) 2020-10-14
HUE066045T2 (hu) 2024-07-28
BR112017016016A2 (pt) 2018-03-20
AU2021203027B2 (en) 2023-07-13
US20200214977A1 (en) 2020-07-09
EP3721868A1 (en) 2020-10-14
BR112017016016B1 (pt) 2023-12-19
CN107427464A (zh) 2017-12-01
EP3250185B1 (en) 2018-12-05
HUE071679T2 (hu) 2025-09-28
US20230140895A1 (en) 2023-05-11
PL4082531T3 (pl) 2024-04-08
KR20170105610A (ko) 2017-09-19
PL3470059T3 (pl) 2020-11-30
ES2704125T3 (es) 2019-03-14
CN107427464B (zh) 2022-04-05
SI4268850T1 (sl) 2025-07-31
CA2975106A1 (en) 2016-08-04
AU2025271194A1 (en) 2025-12-18
PT4082531T (pt) 2023-12-14
AU2023248145B2 (en) 2025-08-28
US10596107B2 (en) 2020-03-24
AU2021203027A1 (en) 2021-06-10
PT4268850T (pt) 2025-06-04
EP4268850B1 (en) 2025-04-16
EP3721868B2 (en) 2025-09-03
ES2924645T5 (en) 2025-12-15
PL3721868T5 (pl) 2025-12-22
EP4082531B1 (en) 2023-10-11
PL3250185T3 (pl) 2019-05-31
PL4268850T3 (pl) 2025-08-04
AU2023248145A1 (en) 2023-11-02
JP2018507252A (ja) 2018-03-15
ES3031414T3 (en) 2025-07-08
MX390671B (es) 2025-03-21
KR102538370B1 (ko) 2023-06-01
US11534395B2 (en) 2022-12-27
EP3250185A1 (en) 2017-12-06
PT3721868T (pt) 2022-08-12
EP3721868B1 (en) 2022-06-01
HUE048564T2 (hu) 2020-08-28
AU2016211745A1 (en) 2017-08-31
MX2017009699A (es) 2017-10-23
US20160213609A1 (en) 2016-07-28
ES2924645T3 (es) 2022-10-10
WO2016123079A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
SG10201707617VA (en) Ophthalmic composition
GB2556619B (en) Suspension compositions
HUE066045T2 (hu) Szemészeti szuszpenzió kompozíció
GB201519811D0 (en) Ocular compositions
GB201619525D0 (en) Ophthalmic composition
TWI563311B (en) Eyeglasses
SG11201707117SA (en) Ophthalmic composition
PL3446682T3 (pl) Kompozycja okulistyczna
ZA201703701B (en) Ophthalmic composition
GB2570376B (en) Suspension compositions
IL251590A0 (en) Ophthalmic preparations
GB2556252B (en) Suspension arrangement
PT3093169T (pt) Mecanismo de suspensão
PT3470059T (pt) Composição de suspensão oftálmica
GB201516201D0 (en) Suspension
GB201501337D0 (en) Suspension arrangement
AU201610412S (en) Sunglasses
GB201421944D0 (en) Suspension bridges
GB201421938D0 (en) Suspension bridges
GB201421941D0 (en) Suspension bridges
GB201511428D0 (en) Stabilizer
GB201518525D0 (en) Spectacles
GB201403864D0 (en) Suspension Bridge
GB201401432D0 (en) Suspension bridge
GB201501223D0 (en) Novel eyeglasses